Breakthrough research and treatment in blood cancers
Call Us: (03) 8560 4010 Fax: (03) 8560 4019
Opening Hours: Monday - Friday, 9am to 5pm

Dr Simon Gibbs

Dr Simon Gibbs



Dr Simon Gibbs
T. (03) 8560 4010
Fax. (03) 8560 4019
Email Us


Clinical Haematologist



Dr Simon Gibbs is a clinical haematologist and amyloidosis specialist, and a Senior adjunct lecturer at Monash University.

Dr Gibbs manages most forms of blood disease, but he is nationally recognised for his work in myeloma and amyloidosis, and has a keen interest in treatment of patients with acute leukaemia and myelodysplasia.

Dr Gibbs attained his medical degrees from the University of Melbourne in 1997. His specialist Haematology training was conducted at the Peter MacCallum Cancer Centre, St Vincent’s Hospital Melbourne, Royal Melbourne Hospital and the Australian Red Cross Blood Service before moving to Cambridge in the United Kingdom to gain further experience in autologous and allogeneic bone marrow transplantation as treatment for myeloma and leukaemia.

Dr Gibbs completed a four year fellowship at the National Amyloidosis Centre at University College London, focusing on novel therapies for AL amyloidosis, the role of solid organ transplantation, and characterising the features and outcomes of patients with ATTR or hereditary amyloidosis.

Subsequently, Dr Gibbs took up an appointment at the Manchester Royal Infirmary, one of the largest cancer-treating hospitals in the North of England, as the Myeloma and Clinical Trials Lead for the Haematology service.

Dr Gibbs returned to Australia in 2014 where he was appointed the Myeloma Lead at Eastern Health. That same year, Dr Gibbs established the Victorian and Tasmanian Amyloidosis Service (VTAS), a multi-disciplinary team of physicians committed to raising awareness, clinical research, drug availability and supportive care for amyloidosis patients throughout south-eastern Australia.

Dr Gibbs is the Chair of the Australian Amyloidosis Network (, and a member of the Haematology Society of Australian and New Zealand (HSANZ). He serves on both the Educational Subcommittee for the International Society of Amyloidosis, and the Medical and Scientific Advisory Committee (MSAG) for Myeloma Australia. He is a member of Australasian Leukaemia and Lymphoma Group (ALLG), where he leads a novel collaborative study with the French IFM research group. He has represented Asia-Pacific countries on steering committees and advisory boards for several global clinical studies.

Dr Gibbs is an author of over 40 publications in international medical literature, including the New England Journal of Medicine, Journal of Clinical Oncology, Nature Reviews and Blood. He is the lead author of the national MSAG Guidelines on Management of Systemic AL Amyloidosis.

Specialist qualifications

Bachelor of Medicine; Bachelor of Surgery from University of Melbourne

Fellow of the Royal Australasian College of Physicians

Fellow of the Royal College of Pathologists of Australasia


Daratumumab-based Treatment for Immunoglobulin Light-Chain Amyloidosis 

Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL

New England Journal of Medicine 2021 Jul 1;385(1):46-58


Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

Nizar J. Bahlis, Rachid Baz, Simon Harrison, Hang Quach, Shir-Jing Ho, Annette Juul Vangsted, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Sheryl Coppola, Xiaoqing Yang, Abdullah Al Masud, Jeremy Ross, Orlando Bueno, and Jonathan Kaufman

Journal of Clinical Oncology 2021 (39):3602-3612


The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group

Nelson Leung, Frank Bridoux, V Batuman, Aristeidis Chaidos, P Cockwell, Vivette D’Agati, Angela Dispenzieri, Fernando Fervenza, JP Fermand, Simon Gibbs, Julian Gillmore, Guillermo Herrera, Arnaud Jaccard, Dragan Jevremovic, Efstathios Kastritis, Vishal Kukreti, Robert Kyle, Helen Lachmann, Christopher Larsen, Heinz Ludwig, Glen Markovic, Giampaolo Merlini, Peter Mollee, Maria Picken, Vincent Rajkumar, Virginie Royal, Paul Sanders, Sanjeev Sethi, Christopher Venner, Peter Voorhees, Ashutosh Wechalekar, Brendan Weiss Samih Nasr

Nature Reviews Nephrology, 2019;15:45-59


European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis

Sajitha Sachchitanantham, Murielle Roussel, Giovanni Palladini, Jean Paul Fermand, Shameem Mahmood, Julian Gillmore, Helen Lachmann, Chris Venner, Simon DJ Gibbs, Philip N Hawkins, Arnaud Jaccard, Giampaolo Merlini and Ashutsoh Wechalekar

J Clin Oncol. 2016 Jun 10;34(17):2037-45.


Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis

Murielle Roussel, Sajitha Sachchithanantha, Simon DJ Gibbs, Christopher P Venner, Jennifer H Pinney, Julian D Gillmore, Helen J Lachmann, Philip N Hawkins and Ashutosh D Wechalekar

British Journal of Haematology 2013 Sep; 162 (6): 856-8


Systemic amyloidosis in England: an epidemiological study

Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, Dungu J, Banypersad SM, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD.

British Journal of Haematology 2013 May;161(4):525-32.


Cyclophosphamide, bortezomib and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression free survival

Christopher P Venner, Thirusha Lane, Darren Foard, Lisa Rannigan, Simon DJ Gibbs, Jennifer H Pinney, Carol J Whelan, Helen J Lachmann, Julian D Gillmore, Philip N Hawkins and Ashutosh D Wechalekar

Blood 2012 May 10;119(19):4387-90


Outcome in renal AL amyloidosis after chemotherapy

Jennifer H Pinney, Helen J Lachmann, L Bansi, Ashutosh D Wechalekar, Janet A Gilbertson, Dorota M Rowczenio, Prayman T Sattianayagam, Simon DJ Gibbs, E Orlandi, Nancy L Wassef, Arthur R Bradwell, Philip N Hawkins and Julian D Gillmore.

Journal of Clinical Oncology 2011 Feb 20;29(6):674-81.



Malvyn Benjamin and Simon DJ Gibbs

British Medical Journal 2011 Nov;343:d6326


Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative    disorders

Simon DJ Gibbs, David A Westerman, Christopher McCormack, John F Seymour and H Miles Prince.

British Journal of Haematology, 2005 June; 130 (1): 87–91